Novartis beats expectations for third quarter

Core earnings per share ended the period at a higher level than analysts' estimates for Novartis's Q3.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Novartis finishes the third quarter of the year better than analysts had anticipated, including outperforming in core earnings per share (EPS), reports Bloomberg News.

Consensus estimates collected by Bloomberg News put Novartis's net sales at USD 13bn, but Novartis has marginally exceeded that figure with reported Q3 net sales figures of USD 13.03bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs